These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Increased urinary excretion of sulfated 3,3',5-triiodothyronine in patients with nodular goiters receiving suppressive thyroxine therapy. Huang WS, Kuo SW, Chen WL, Fuh MM, Wu SY. Thyroid; 1996 Apr; 6(2):91-6. PubMed ID: 8733878 [Abstract] [Full Text] [Related]
3. Thyroxine sulfate is a major thyroid hormone metabolite and a potential intermediate in the monodeiodination pathways in fetal sheep. Wu S, Polk D, Wong S, Reviczky A, Vu R, Fisher DA. Endocrinology; 1992 Oct; 131(4):1751-6. PubMed ID: 1396320 [Abstract] [Full Text] [Related]
4. A radioimmunoassay for measurement of thyroxine sulfate. Chopra IJ, Santini F, Hurd RE, Chua Teco GN. J Clin Endocrinol Metab; 1993 Jan; 76(1):145-50. PubMed ID: 8421080 [Abstract] [Full Text] [Related]
5. Identification of thyroxine-sulfate (T4S) in human serum and amniotic fluid by a novel T4S radioimmunoassay. Wu SY, Huang WS, Polk D, Florsheim WH, Green WL, Fisher DA. Thyroid; 1992 Jan; 2(2):101-5. PubMed ID: 1525576 [Abstract] [Full Text] [Related]
6. Changes in serum thyroid hormone, thyrotropin and thyroglobulin concentrations during thyroxine therapy in patients with solitary thyroid nodules. Morita T, Tamai H, Ohshima A, Komaki G, Matsubayashi S, Kuma K, Nakagawa T. J Clin Endocrinol Metab; 1989 Aug; 69(2):227-30. PubMed ID: 2753971 [Abstract] [Full Text] [Related]
7. Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH. Persani L, Preziati D, Matthews CH, Sartorio A, Chatterjee VK, Beck-Peccoz P. Clin Endocrinol (Oxf); 1997 Aug; 47(2):207-14. PubMed ID: 9302396 [Abstract] [Full Text] [Related]
8. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study. Appetecchia M. Horm Res; 2005 Aug; 64(6):293-8. PubMed ID: 16269872 [Abstract] [Full Text] [Related]
9. Increased thyroidal T4/T3 ratio in nodular and paranodular tissues of nontoxic goiter following suppressive treatment with thyroid hormones. Solter M, Tislarić D, Pegan B, Petric V, Sekso M. Horm Res; 1987 Aug; 25(3):147-51. PubMed ID: 3570153 [Abstract] [Full Text] [Related]
10. Effects of propylthiouracil on the biliary clearance of thyroxine (T4) in rats: decreased excretion of 3,5,3'-triiodothyronine glucuronide and increased excretion of 3,3',5'-triiodothyronine glucuronide and T4 sulfate. Rutgers M, Pigmans IG, Bonthuis F, Docter R, Visser TJ. Endocrinology; 1989 Oct; 125(4):2175-86. PubMed ID: 2791984 [Abstract] [Full Text] [Related]
11. Serum iodothyronine concentrations in intestinally decontaminated rats treated with a 5'-deiodinase type I inhibitor 6-anilino-2-thiouracil. Veronikis IE, Alex S, Fang SL, Wright G, Wu SY, Chanoine JP, Emerson CH, Braverman LE. Eur J Endocrinol; 1996 Apr; 134(4):519-23. PubMed ID: 8640307 [Abstract] [Full Text] [Related]
12. Relationship between T4, T3 and T4/T3 ratio in thyroid tissue, thyroid and peripheral veins in patients with nontoxic nodular goiter. Solter M, Tislarić D, Petric V, Pegan B. Exp Clin Endocrinol; 1989 Apr; 94(3):305-12. PubMed ID: 2630310 [Abstract] [Full Text] [Related]
13. Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter. Güllü S, Gürses MA, Başkal N, Uysal AR, Kamel AN, Erdoğan G. Endocr J; 1999 Feb; 46(1):221-6. PubMed ID: 10426591 [Abstract] [Full Text] [Related]
14. Triiodothyronine and thyroxine in urine. I. Measurement and application. Shakespear RA, Burke CW. J Clin Endocrinol Metab; 1976 Mar; 42(3):494-503. PubMed ID: 1254690 [Abstract] [Full Text] [Related]